About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Treatment of Aggressive Localized Lymphoma | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 3NCT00841945

Treatment of Aggressive Localized Lymphoma

Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma...

Lead sponsor: French Innovative Leukemia Organisation•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

French Innovative Leukemia Organisation

CHOP 14 R regimen of chemotherapy is a good standard in the treatment of agressive and localized B lymphoma. Interest of the radiotheraphy

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age \> 18 and \< 75 years
•Diffuse B large cell lymphoma , CD 20+
•Ann Arbor stage I or II withe a bulk \<7 cm
•stage i ou II confirmed by the PET-scan
•No previously treated
•HIV negative
•Signed Informed consent

Exclusion Criteria

•Age\< 18 and \> 75 years
•other type of lymphoma
•CD20 negative
•Ann Arbor stage \>II or bulk \> 7 cm
•HIV positive
•Contraindication to Rituximab use according to Sm PC
•Containdication to antracyclin
•cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma
•Refusal of sign the informed consent

Related studies

RECRUITINGPhase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT07523737 · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 1

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

RECRUITINGPhase 1/2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more

RECRUITINGPhase 1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 23, 2017Terms

Trial snapshot

StatusTERMINATED

PhasePHASE3

Enrollment334

Start dateApr 2005

Last updatedFeb 23, 2017

Condition

B Cell Lymphoma

Locations shown

Regional university hospital

Rennes

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions